Skip to main content

Curetis Gets CE Mark for UTI Test

NEW YORK (GenomeWeb) – Dutch diagnostics firm Curetis announced today that it has received CE-IVD marking for its Unyvero UTI test cartridge for the diagnosis of severe urinary tract infections.

The PCR-based cartridge runs on the company's Unyvero platform — which was approved in the US earlier this month and received CE marking in 2012 — and covers 103 diagnostic targets. It detects 88 pathogens, including Gram-positive and Gram-negative species, as well as anaerobic bacteria and the pathogenic fungus Candida auris. It also detects 15 genetic markers of antibiotic resistance.

The cartridge is set for commercial launch in Europe later this month.

"This new product further enhances our portfolio of Unyvero cartridges for hospital-acquired infections," Curetis Chief Business Officer Achim Plum said in a statement. "With the launch of Unyvero UTI, clinicians now have access to Unyvero cartridges that cover all primary infections [that] may lead to sepsis."

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.